Lacosamide-structure (Lacosamide Structure)
Lacosamide Injection
Product Images NDC 68083-480
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 68083-480). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Lacosamide-carton-label (Lacosamide Carton Label)
This is a medication guide for Lacosamide Injection. Each single-dose vial contains a solution for infusion of 200 mg/20 mL of the active ingredient, lacosamide. The medication is only for intravenous use and the usual dosage should be determined by a physician. The solution also contains inactive ingredients including sodium chloride, hydrochloric acid, and water for injection. The medication should be stored between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F) and should be kept out of reach of children. The medication is manufactured by Gland Pharma Limited in Hyderabad, India.*
Lacosamide-container-label (Lacosamide Container Label)
Lacosamide Injection, USP manufactured by Gland Pharma Limited in Hyderabad, India with an ANDS ML No of 2/MD/TS/2016/F/6 and PSLAB-XXXXXX-XX. The injection contains 200mg/20mL of 10mg/mL Lacosamide for IV use only. It is essential to read package insert for dosages and discard unused portions. The injection should be kept at a controlled room temperature and away from children. It is a single-dose vial that has an NDC of 68083-480-10 for Rx only.*
Lacosamide-figure-1 (Lacosamide Figure 1)
Lacosamide-figure-2 (Lacosamide Figure 2)
This appears to be a figure or graph showing the Responder Rate for Lacosamide and Placebo groups in Studies 2, 3, and 4. The figure shows the proportion of patients who responded to treatment, with Lacosamide and Placebo being compared. Unfortunately, without the actual graph it is difficult to provide more detail.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
